Viracta Therapeutics, Inc.

Equities

VIRX

US92765F1084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8283 ^USD	-2.21%		-3.32%	+45.32%

Apr. 15	Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	CI
Apr. 01	Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	CI

Viracta Therapeutics to Present at Upcoming Investor Conferences

November 07, 2023 at 04:15 pm EST

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Company’s Management will participate in upcoming investor conferences in November.

Details on the conferences can be found below:

Stifel 2023 Healthcare Conference
Presentation Date: Wednesday, November 15, 2023
Presentation Time: 10:20 – 10:50 AM ET

Piper Sandler 35^th Annual Healthcare Conference
Presentation Date: Tuesday, November 28, 2023
Presentation Time: 12:10 – 12:30 PM ET

6^th Annual Evercore ISI HealthCONx Conference
Presentation Date: Wednesday, November 29, 2023
Presentation Time: 3:25 – 3:45 PM ET

A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" and archived for 90 days.

About Viracta Therapeutics, Inc.
Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory Epstein-Barr virus-positive (EBV⁺) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of patients with recurrent or metastatic EBV⁺ nasopharyngeal carcinoma and other advanced EBV⁺ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

SOURCE Viracta Therapeutics, Inc.

Source: Viracta Therapeutics, Inc.

2023 GlobeNewswire, Inc., source Press Releases

Latest news about Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	Apr. 15	CI
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	Apr. 01	CI
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	Mar. 21	MT
Viracta Therapeutics, Inc. Announces Executive Changes	Mar. 20	CI
Viracta Therapeutics, Inc. Announces Chief Financial Officer Changes	Mar. 20	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Viracta Therapeutics, Inc. Provides Clinical Update	Jan. 04	CI
Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels	Dec. 04	CI
RBC Cuts Price Target on Viracta Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	Nov. 10	MT
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy	23-10-31	MT
Transcript : Viracta Therapeutics, Inc. - Special Call	23-10-04
Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Viracta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer	23-08-08	CI
HC Wainwright Lowers Price Target on Viracta Therapeutics to $10 From $33, Maintains Buy Rating	23-07-05	MT
Viracta Therapeutics to Expand Cohort of Patients in Virus-Associated Cancers Clinical Trial	23-06-28	MT
Viracta Therapeuticsâ€™ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma	23-06-28	CI
RBC Cuts Price Target on Viracta Therapeutics to $7 From $8, Maintains Outperform, Speculative Risk Rating	23-05-09	MT
Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Viracta Therapeutics, Inc. Announces Departure of Lisa Rojkjaer as Chief Medical Officer	23-05-02	CI
Viracta Therapeutics, Inc. Announces Nicole Onetto Will Not Stand for Re-Election as Director	23-03-31	CI

Chart Viracta Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Companyâs lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8283 USD

Average target price

7 USD

Spread / Average Target

+745.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIRACTA THERAPEUTICS, INC.	+45.32%	32.53M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research